

Sydney, Australia – Wednesday 19th October 2011

Link Healthcare announces licence deal for Relistor®

Link Healthcare today announced it had been granted a licence to market Relistor® (methylnaltrexone) in Australia, New Zealand, South Africa and Asia from Salix Pharmaceuticals, Inc. of North Carolina, USA. Relistor subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

Relistor is a peripherally acting mu-opioid receptor antagonist that counteracts the constipating effects of opioid pain medications in the gastrointestinal tract without affecting the ability to relieve pain. Relistor was approved in Australia in 2009 and the drug is currently approved for use in over 50 countries.

Commenting on the licensing agreement, Carolyn Logan, President and Chief Executive Officer, of Salix Pharmaceuticals Inc., said the agreement with Link Healthcare “met a priority need to have a competent and experienced partner with the skills, experience and passion to effectively market and develop Relistor in Asia Pacific and South Africa.

“With the strength of Link Healthcare’s specialty product focus and development team behind this product, we believe that Relistor can achieve its full potential in these markets to the benefit of OIC patients.”

John Bacon, CEO of Link Healthcare, said his company, which has established a strong base in drugs nominated as fulfilling a strong clinical need, was anticipating a steady and increasing demand for Relistor.

“We are excited to add Relistor, a first-in-class treatment for OIC in advanced illness to the Link Healthcare product portfolio,” Mr Bacon said.

“Constipation is a common and often debilitating consequence of using opioid analgesics in the management of pain. Link has been extending its marketing footprint over the past year through our South African partnership with the Equity Pharma Group and in Asia through our growing business base in Hong Kong.

"We are looking forward to fully activating this network to provide assistance to physicians across a wide region in addressing opioid-induced constipation," Mr Bacon added.

Link Healthcare will market Relistor through a specialty sales force in Australia and New Zealand. In other countries specified in the licence Relistor will be marketed through established strategic partnerships. Salix and Link plan to transition commercial responsibility of Relistor from Pfizer Inc (the current sponsor of Relistor in the licensed territories) during October 2011.

Ends

Further Information:

John Bacon, CEO Link Healthcare

(ph) +61 (0)2 8401 9777

About Link

LINK Healthcare is a privately owned Australian specialist Pharmaceutical and Medical Technology business. LINK's mission is to strive for excellence in the marketing of a vitally important and unique range of specialist pharmaceutical and medical products in the Asia-Pacific and Southern African regions.

www.linkhealthcare.com.au

About Salix

Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North Carolina, develops and markets prescription pharmaceutical products for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic drugs, complete any required development and regulatory submission of these products, and market them through the Company's gastroenterology specialty sales and marketing team.

www.salix.com